These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
165 related articles for article (PubMed ID: 5068023)
21. [The effect of amantadine in parkinsonism: clinical and neurophysiological findings]. Fünfgeld EW Dtsch Med Wochenschr; 1970 Sep; 95(36):1834-6. PubMed ID: 5453004 [No Abstract] [Full Text] [Related]
22. Syndrome of inappropriate antidiuretic hormone secretion possibly associated with amantadine therapy in Parkinson disease. Alonso Navarro H; Sánz-Aiz A; Izquierdo L; Jiménez Jiménez FJ Clin Neuropharmacol; 2009; 32(3):167-8. PubMed ID: 19483487 [TBL] [Abstract][Full Text] [Related]
23. Amantadine in Parkinson's disease: pro and contra. Greulich W; Fenger E J Neural Transm Suppl; 1995; 46():415-21. PubMed ID: 8821077 [TBL] [Abstract][Full Text] [Related]
24. [Dopaminergic agents, COMT inhibitors or amantadine? Proper treatment for your Parkinson patient]. Ceballos-Baumann AO MMW Fortschr Med; 2002 May; Suppl 2():37-43. PubMed ID: 12070848 [TBL] [Abstract][Full Text] [Related]
25. [Effects of amantadine on the state of consciousness in diffuse cerebral psychosyndromes caused by vascular disorders]. Vitetta M Minerva Med; 1971 Oct; 62(82):3984-6. PubMed ID: 5125059 [No Abstract] [Full Text] [Related]
26. [Experience in the prolonged use of midantan (amantadine hydrochloride) in parkinsonism]. Man'kovskii NB; Vainshtok AB; Oleinik LI Zh Nevropatol Psikhiatr Im S S Korsakova; 1973; 73(4):524-30. PubMed ID: 4705407 [No Abstract] [Full Text] [Related]
27. Differentiation of tardive dyskinesias and drug-induced Parkinsonism. N Engl J Med; 1971 Jun; 284(24):1382-4. PubMed ID: 5576464 [No Abstract] [Full Text] [Related]
28. Twenty-five years of amantadine therapy in Parkinson's disease. Danielczyk W J Neural Transm Suppl; 1995; 46():399-405. PubMed ID: 8821075 [TBL] [Abstract][Full Text] [Related]
30. [Long-term therapy of the Parkinson syndrome]. Ludin HP Schweiz Med Wochenschr; 1984 Aug; 114(33):1131-6. PubMed ID: 6484543 [TBL] [Abstract][Full Text] [Related]
31. Anticholinergic syndrome with severe rhabdomyolysis--an unusual feature of amantadine toxicity. Yang CC; Deng JF Intensive Care Med; 1997 Mar; 23(3):355-6. PubMed ID: 9083247 [No Abstract] [Full Text] [Related]
32. [Effects of amantadine therapy on sleep spindles in patients with parkinsonism and comparative analysis of L-dopa effects]. Puca FM; Pigneri MT Boll Soc Ital Biol Sper; 1972 May; 48(9):237-40. PubMed ID: 5070096 [No Abstract] [Full Text] [Related]
33. Amantadine-induced livedo reticularis: a report of two cases. Hayes BB; Cook-Norris RH; Miller JL; Rodriguez A; Zic JA J Drugs Dermatol; 2006 Mar; 5(3):288-9. PubMed ID: 16573266 [TBL] [Abstract][Full Text] [Related]
34. [Amantadine in the treatment of transitory hypokinesia in patients with parkinsonism during therapy with L-Dopa]. De Divitiis E; D'Andrea F; Signorelli CD; Cerillo A Minerva Med; 1971 Oct; 62(82):4007-8. PubMed ID: 5125065 [No Abstract] [Full Text] [Related]
35. [Drug therapy of parkinsonism]. Teräväinen H; Larsen TA Duodecim; 1982; 98(11):892-900. PubMed ID: 6125373 [No Abstract] [Full Text] [Related]
36. Rimantadine in Parkinson's disease patients experiencing peripheral adverse effects from amantadine: report of a case series. Singer C; Papapetropoulos S; Gonzalez MA; Roberts EL; Lieberman A Mov Disord; 2005 Jul; 20(7):873-7. PubMed ID: 15809995 [TBL] [Abstract][Full Text] [Related]